Helicobacter pylori Resistance: New Natural Candidates for Therapeutical Approach
A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Bacterial Pathogens".
Deadline for manuscript submissions: closed (15 February 2022) | Viewed by 23223
Special Issue Editors
Interests: study of the effects of drugs on the internalization process of Helicobacter pylori; molecular studies of resistance to antimicrobial agents; effect of new molecules against H. pylori in sessile and planktonic form; pathogenicity of H. pylori; antimicrobial susceptibility testing of H. pylori to new synthetized drugs.
Special Issues, Collections and Topics in MDPI journals
Interests: microbial biofilms; Helicobacter pylori; Lactobacillus reuteri; outer membrane vesicles; extracellular DNA; antimicrobial/antibiofilm activity; human microbiome; probiotics; prebiotics and symbiotics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Helicobacter pylori is associated with the development of gastritis, peptic and duodenal ulcers, gastric mucosa-associated lymphoid tissue (MALT) lymphoma and gastric cancer. It has been demonstrated that the eradication o H. pylori infection represents an important approach for preventing gastric cancer development.
The persistent increase in resistance versus the antimicrobial drugs commonly used in clinical practice represents one of the biggest concerns of global health. In particular, the resistance rate to clarithromycin is 30% in Italy and Japan, and 40% and 50% in Turkey and China, respectively, so that the resistance against the clarithromycin has been defined by World Health Organization as “a high priority for antibiotic research and development”. Hence, the identification of new therapeutical strategies based on the use of new molecules/compounds of natural origin that do not induce resistance and show efficacy against H. pylori eradication becomes necessary.
The survival and persistence of the microorganism in the human host is due to both its genetic variability and its capability to develop biofilm as well as to enter the viable but nonculturable (VBNC) state. H. pylori develops a well-structured biofilm both in vivo and in vitro. The multifactorial nature of biofilm formation and drug tolerance requires the use of multitarget or combinational therapeutical approaches.
The aim of the present Special Issue is to collect articles focalized on the identification and characterization of (i) New molecules/compounds of natural origin with antibacterial and/or antibiofilm activities used alone or in combination with antimicrobials used in therapy. In particular, it will be of interest to look at biofilm removal strategies/compounds for the eradication of a mature biofilm as well as for the inhibition of biofilm formation to manage H. pylori biofilm infections in clinical practice; (ii) Probiotics or molecules/compounds derived from probiotics as well as the use of postbiotics and symbiotics for the eradication of H. pylori. Submissions of original research articles, commentaries, review articles, opinion articles, or hypothesis and theory articles are encouraged.
Dr. Francesca Sisto
Dr. Rossella Grande
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Helicobacter pylori
- antimicrobial activity
- antibiofilm activity
- biofilm
- probiotics
- postbiotics
- symbiotics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.